New drug targets rare lung disease in early trial
NCT ID NCT06633757
First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study tested an experimental drug called RCT1100 in 14 adults with primary ciliary dyskinesia (PCD) caused by a specific gene change (DNAI1). PCD makes it hard for the lungs to clear mucus, leading to frequent infections. The goal was to see if RCT1100 is safe and can improve how well the lungs clear mucus. This is an early-stage trial, so results will help plan future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CILIARY DYSKINESIA (PCD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Copenhagen University Hospital - Rigshospitalet
Copenhagen, 2100, Denmark
-
Münster University Hospital, Albert-Schweitzer-Campus 1
Münster, North Rhine-Westphalia, 48149, Germany
-
UNC
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.